NCT06358703View on ClinicalTrials.gov

Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

Not yet recruitingOBSERVATIONAL
Enrollment

116

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Immune Thrombotic Thrombocytopenia
Interventions
DRUG

Caplacizumab

Early Caplacizumab use

Trial Locations (1)

43125

USTMA, Groveport

All Listed Sponsors
lead

US Thrombotic Microangiopathy Alliance

OTHER

NCT06358703 - Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors | Biotech Hunter | Biotech Hunter